BMY

On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for ATR 1072 and the launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying […]

Yahoo · 7h ago

BMY shows a strong breakout setup: 10/10 technical rating, 9/10 setup score. Rising moving averages and a buy stop at $68.10 make it one to watch.

ChartMill · 1d ago

Bristol Myers Squibb's aggressive M&A and in-house R&D efforts have driven the portfolio renewal cadence and ongoing valuation re-rating. Click for more on BMY.

SeekingAlpha · 1d ago

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.

Yahoo · 1d ago

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and

Yahoo · 1d ago

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H

Yahoo · 2d ago

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.

Benzinga · 2d ago